“The Story of My Life” – An Autobiography of Suzetrigine

Hello…

I am Suzetrigine.

A new name in the world of pain management… but a revolutionary one.

For decades, humans searched for a pain medicine that could relieve suffering without addiction, sedation, or opioid dependence.

Many drugs tried.

Many pathways failed.

Then… I arrived.

This is my story — the story of a next-generation non-opioid analgesic designed to change the future of pain therapy.

---

🧬 Chapter 1 – The Era Before Me

For years, pain management relied heavily on:

• Opioids
• NSAIDs
• Acetaminophen

Each helped patients… but each carried limitations.

⚠️ Opioids caused addiction and respiratory depression

⚠️ NSAIDs damaged stomach and kidneys

⚠️ Long-term therapies created serious concerns

Scientists asked an important question:

👉 “Can pain be stopped before it reaches the brain?”

That question led to my birth.

---

🔬 Chapter 2 – My Discovery

I was developed by:

Vertex Pharmaceuticals

During my research phase, I was known as:

VX-548

Researchers focused on a very specific target:

🧪 NaV1.8 Voltage-Gated Sodium Channel

This channel exists mainly in:

👉 Peripheral pain-sensing neurons

👉 Dorsal root ganglion neurons

Unlike opioids, my mission was different.

I would:

✔ Block pain signals in the peripheral nervous system

✔ Avoid the addictive reward pathways of the brain

That made me unique.

---

⚙️ Chapter 3 – My Mechanism of Action

Pain travels through nerves using electrical impulses.

These impulses depend on sodium channels opening and allowing sodium ions to enter nerve cells.

One important pain-specific channel is:

🧬 NaV1.8

I selectively bind to this channel and stabilize it in its closed state.

My mechanism looks like this:

Result:

✔ Reduced action potentials

✔ Reduced pain signal propagation

✔ Pain relief without opioid activity

And because NaV1.8 is mainly peripheral:

👉 I avoid major CNS effects and addictive potential.

---

🌍 Chapter 4 – My Rise to Recognition

Clinical trials showed something remarkable.

I effectively reduced:

✔ Acute postoperative pain

✔ Moderate-to-severe pain

And I did this:

✅ Without causing opioid-like dependence

This attracted major attention worldwide.

In 2025, I received:

US FDA Approval

I became:

👉 The first new class of non-opioid analgesic approved in more than 20 years.

---

💊 Chapter 5 – My ADME Journey

Every medicine has a pharmacokinetic story.

Here is mine.

---

🅰️ Absorption

I am administered orally.

After entering the gastrointestinal tract:

✔ I am absorbed into systemic circulation

✔ My initial dose is recommended on an empty stomach for faster onset

Food may delay my absorption.

That’s why patients are advised:

👉 Take the first dose at least 1 hour before or 2 hours after food.

---

🅳 Distribution

Once absorbed:

✔ I circulate through the bloodstream

✔ Reach peripheral sensory neurons

✔ Act primarily outside the central nervous system

My selectivity toward peripheral NaV1.8 channels helps minimize CNS adverse effects.

---

🅼 Metabolism

My metabolism mainly occurs in the liver.

The major enzyme involved is:

🧪 CYP3A4

This is extremely important because many medicines and foods influence CYP3A4 activity.

I also produce an active metabolite:

M6-SUZ

Though less potent than me, it still contributes to activity.

---

🅴 Excretion

After metabolism:

✔ My metabolites are eliminated from the body

✔ Primarily through hepatic metabolic pathways and excretory processes

Patients with severe liver impairment require caution.

---

⚠️ Chapter 6 – Drug–Drug Interactions

Because I depend on CYP3A4 metabolism, interactions are very important.

---

🚫 Strong CYP3A4 Inhibitors

Examples:

• Ketoconazole
• Clarithromycin
• Ritonavir

These drugs:

👉 Increase my concentration in blood

Result:

⚠️ Increased adverse effects

Some combinations are contraindicated.

---

⚡ CYP3A4 Inducers

Examples:

• Rifampin
• Carbamazepine
• Phenytoin

These drugs:

👉 Increase my metabolism

Result:

⚠️ Reduced efficacy

Pain relief may become inadequate.

---

💊 Interaction with Hormonal Contraceptives

I may reduce effectiveness of certain hormonal contraceptives.

Therefore:

👉 Additional nonhormonal contraception may be necessary during therapy.

---

🍊 Chapter 7 – Drug–Food Interaction

One food became especially important in my life:

🍊 Grapefruit Juice

Grapefruit inhibits CYP3A4.

When consumed with me:

👉 My plasma concentration may increase

Result:

⚠️ Increased side effect risk

That’s why patients are advised:

🚫 Avoid grapefruit and grapefruit juice during therapy.

---

⚖️ Chapter 8 – My Advantages

What makes me different?

✔ Non-opioid analgesic

✔ No significant addictive potential

✔ Peripheral mechanism of action

✔ Minimal CNS depression

✔ Novel NaV1.8 targeting

I represent a new era in pain medicine.

---

⚠️ Chapter 9 – My Limitations

Even I have challenges.

Possible adverse effects include:

⚠️ Muscle spasms

⚠️ Rash

⚠️ Itching

⚠️ Elevated creatine phosphokinase (CPK)

And because I am still new:

👉 Long-term clinical experience is evolving.

---

❤️ My Message

I was born from one important goal:

👉 To relieve pain without creating addiction.

I am not an opioid.

I am not an NSAID.

I am part of a new generation of precision pain therapeutics.

---

✨ Epilogue

From the laboratories of modern drug discovery…

To becoming a breakthrough non-opioid analgesic…

This is my journey.

I am Suzetrigine — the selective silencer of pain signals.